ストックスクリーナーアプリを入手
3.34
0.60%
0.02
プレマーケット:
3.35
0.01
+0.30%
前日終値:
$3.32
開ける：
$3.35
24時間の取引高:
215.12K
Relative Volume:
0.15
時価総額：
$3.18M
収益：
-
当期純損益:
$-5.85M
株価収益率:
-0.4994
EPS:
-6.6877
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
-15.87%
1か月 パフォーマンス:
-43.61%
6か月 パフォーマンス:
-69.07%
1年 パフォーマンス:
-93.13%
1日の値動き範囲:
$3.29
$3.3999
1週間の範囲:
$3.28
$4.00
52週間の値動き範囲:
$3.0558
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
ALZN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
3.34 | 3.18M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-01 | 開始されました | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc (ALZN) 最新ニュース
Citadel Advisors LLC Makes New Investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Growth in Short Interest - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 18.6% in May - Defense World
Promising Pharmaceutical Stocks To Follow Today – May 29th - Defense World
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen - Defense World
Lithium Stocks To Consider – May 29th - Defense World
Alzamend Neuro begins phase II trial for novel lithium delivery system By Investing.com - Investing.com South Africa
Alzamend Neuro doses first patient in Phase II study of AL001 - TipRanks
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | - GuruFocus
Sector Update: Health Care - marketscreener.com
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Asianet Newsable
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled By Stocktwits - Investing.com India
Lithium Stocks To ConsiderMay 29th - MarketBeat
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone - Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - Benzinga
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks
Alzamend Neuro Soars on Breakthrough Trial News: Is This Biotech Stock a Hidden Gem? - RagingBull
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Alzamend Neuro begins phase II trial for novel lithium delivery system - Investing.com Australia
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 "Lithium In Brain" Study - marketscreener.com
Alzamend Neuro Announces Dosing of First Patient in its - GlobeNewswire
Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Trading Down 5.5% – Here’s What Happened - Defense World
Alzamend begins phase II trial for novel lithium therapy By Investing.com - Investing.com South Africa
Alzamend begins phase II trial for novel lithium therapy - Investing.com Australia
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Al - GuruFocus
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Alzheimer's Treatment | ALZN Stock News - GuruFocus
Alzamend Neuro Enrolls First Patient in its Phase II - GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study - marketscreener.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
Alzamend Neuro (ALZN) Begins Key Phase II Trials of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 'Lithium in Brain” Study Taking Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Alzamend Neuro to conduct reverse stock split - MSN
Alzamend Neuro adds partners for lithium study using specialty head coil - AuntMinnie
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com India
Alzamend Neuro Announces Reverse Stock Split Plan - TipRanks
Stock Market Recap: Alzamend Neuro Inc (ALZN) Concludes at 0.60, a -6.22 Surge/Decline - DWinneX
Alzamend Neuro (ALZN) Announces Reverse Stock Split | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Reverse Stock Split - The Manila Times
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements - Investing.com
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro partners with Mint Labs to support five upcoming trials - TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered - GlobeNewswire
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical ... - Eagle-Tribune
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program - Yahoo
Geode Capital Management LLC Buys New Stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro Inc (ALZN) 財務データ
収益
当期純利益
現金流量
EPS
Alzamend Neuro Inc (ALZN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.28 |
11 |
58 |
1,843 |
0.92%
7.75%
大文字化:
|
ボリューム (24 時間):